



Global Coordination of Funders investing in Pandemic Preparedness Research

Dr. Charu Kaushic

Scientific Director


Institute of Infection and Immunity (III)

Canadian Institutes of Health Research (CIHR)

Chair

Global Research Collaboration For Infectious

Disease Preparedness (GLOPID-R)



GloPID-R at a Glance

The **Global Research Collaboration for Infectious Disease Preparedness** is an international network of research funding organizations, launched in 2013 arising from discussion at HIRO table and funded by EC.

Current Co-chairs



Charu Kaushic
Chair



Jeremy Farrar
Wellcome Trust



Barbara Kerstiens
European Commission



Shoji Miyagawa
AMED




Yazdan Yazdanpanah
ANRS/EID



Charles Shey Wiysonge
SAMRC

The GloPID-R Secretariat receives funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 874667.



Global Research Collaboration for Infectious Disease Preparedness (GloPID-R)

Goal: To bring together funding organizations investing in research related to new or re-emerging infectious diseases in order to **increase preparedness** and **facilitate rapid research response** to outbreaks with pandemic potential


<h3>Objective 1</h3>	<h3>Objective 2</h3>	<h3>Objective 3</h3>
<p>To support development of research preparedness activities in order to reinforce rapid response capacities</p> <ul style="list-style-type: none"> • Coordinate exchange to foster collaboration between initiatives • Policy development • Develop research agendas with partners 	<p>To facilitate rapid and aligned funding of research in an emergency</p> <ul style="list-style-type: none"> • Identify research priorities with WHO • Organize meetings to identify gaps • Communicate funding and other pandemic activities with members 	<p>To reinforce GloPID-R's visibility and capacity for influence</p> <ul style="list-style-type: none"> • Publish activities in high-impact journals • Enhance relationship with WHO • Engage with policy makers, regulators and industry partners

*Launched in 2013: Conduit for its current 33 members and 7 observer organizations to **exchange information and communicate with WHO and other key stakeholders***

GloPID-R Highlights (2020 – Present)

2020


FEB ● WHO & GloPID-R: Global Research and Innovation forum



APR ● UKCDR & GloPID-R: Live COVID-19 Research Project Tracker

WHO priority research area	GloPID priority sub-areas				Total Funding (Million \$)
	A	B	C	D	
1. Viral, natural history, transmission and control	162	105	174	123	664
2. Animal and environmental research	72	6	7	9	94
3. Epidemiological studies	102	219	72	236	629
4. Clinical characterization and management	144	74	11	27	256
5. Infection prevention and control	136	312	147	309	764
6. Candidate therapeutics R&D	106	85	17	235	423
7. Candidate vaccines R&D	174	41	34	6	255
8. Ethics considerations for research	36	13	30	47	126
9. Social sciences in the outbreak response	119	160	147	179	505
Unallocated					636

JULY ● COVID-19 Research Synergies Meetings



DEC ● ISARIC & GloPID-R: Long COVID Joint Research Forum


COMMENTARY Open

Research priorities for Long Covid: refined through an international multi-stakeholder forum


Gail Carson and Long Covid Forum Group

2021


MAR ● GloPID-R, UKCDR & COVID-19 Clinical Research Coalition: COVID-19 Research in LMICs Virtual Event



AUG ● SAG & Co-Chairs: COVID-19 Research Recommendations & Considerations for GloPID-R, 2021-2023 Report




NOV ● UKCDR & GloPID-R's COVID CIRCLE: 'Funding and undertaking research during the first year of the COVID-19 pandemic: COVID CIRCLE lessons for funders'



2022


FEB ● GloPID-R & UKCDR: Funders roundtable

Brought together funders with WHO and G7 to discuss coordination of funding for clinical trials



Major projects:

- Improve coordination of clinical trials
- Pandemic tracker and policy capacity
- Developing platform for joint or coordinated funding
- Development of regional hubs
- Plus strengthening GloPID-R's governance framework



COVID-19 Research Project Tracker

- Database of funded research projects on COVID-19 helps funders and researchers **identify research gaps and opportunities and inform future research investments**
 - **Complete spectrum of research projects & classifies against the WHO COVID-19 R&D priorities**
 - **>15,000** projects funded by >200 funders, taking place across >140 countries, investment of >\$5B
- Crucial enabler for collaboration & coherence
- Living Systemic Review (Wellcome Open Research)

UPDATE A living mapping review for COVID-19 funded research projects: 18 month update [version 7; peer review: 2 approved]

Previously titled: 'A living mapping review for COVID-19 funded research projects: 15 month update'

Adrian Bucher¹, Emilia Antonio ², Henrike Grund¹, Nusrat Jabin¹, Chantel Jones¹, Meron Kifle¹, Susan Khader ², Genevieve Boily-Larouche³, Morgan Lay⁴, [Alice Norton](#) ²

Funder(s)
Focus
Search Title/Abstract

(All)
(All)

Click on a research area or coloured tile to view the list of projects

WHO priority research area	WHO priority sub-area							Total Funding Amount (\$)
	a	b	c	d	e	f	N/A	
1. Virus: natural history, transmission an..	1,042	822	251	848	153	98	56	969.8M
2. Animal and environmental research	86	7	11				3	20.5M
3. Epidemiological studies	786	323	79	319			194	457.6M
4. Clinical characterization and managem..	635	1,219	11	974	27	7	212	1,327.2M
5. Infection prevention and control	227	356	530	370			219	320.5M
6. Candidate therapeutics R&D	1,049	120	18	305	49		109	794.7M
7. Candidate vaccines R&D	275	44	39	4	18		137	1,728.1M
8. Ethics considerations for research	63	16	31	69	16		32	43.8M
9. Social sciences in the outbreak response	1,099	252	644	211	28	39	2,732	893.6M
Unallocated							903	0.0M

Geographical distribution of COVID-19 therapeutics R&D projects

19,292 funded projects captured in UKCDR & GLoPID-R COVID-19 Research Project Tracker as of 4th November 2022.

UK : 9% of projects
 Canada : 12% of projects

USA: 22% of projects (\$389m)

- \$102m NIH-funded project involving vaccine & therapeutics clinical trial infrastructure in USA, South America & Sub-Saharan Africa.
- Most projects focus on “in vitro and in vivo testing to identify candidates”
- The majority of projects in collaboration with other HICs or UMICs

Germany, France & Japan each involved in 5% of projects



1,808 projects focus on “Candidate therapeutics R&D”




Projects involve **82 countries**

- **60%** of the projects in **6 High income countries**
- **97.3%** of projects involve a **single country**

Involved in 15% of projects




Funding and scope of global COVID-19 therapeutics R&D projects



- **At least \$951m** invested by **206 funders** in “candidate therapeutics R&D”
- Most projects funded by **NIH** with at least **\$356** invested

- **17% (202)** of projects in this sub-priority area involve at least one LMIC
- Highest funded project:
 - **\$42m** invested by the EC in accelerated therapeutics in Europe
 - Focus on identifying new drugs candidates and repurposed drugs




- **15% (52)** of projects in this sub-priority area involve at least one LMIC
- Highest funded project:
 - **\$9m** NIH-funded randomized, placebo-controlled trial evaluating of **Hydroxychloroquine** and **Azithromycin** in SARS-CoV-2 infected persons

Pandemic Preparedness: Analytical Capacity and Funding Tracking programme (Pandemic PACT)

Supported to date by (including grants in preparation): EDCTP with UKDHSC; IDRC; Wellcome

In kind support provided by: ZonMW



Abbreviations: CEPI: Coalition for Epidemic Preparedness Innovations, RRNA: Rapid Research Needs Appraisal, WHO: World Health Organization

Coordinated Funding-Proposed delivery model

- After extensive consultation and discussion: adaptation of GACD designed for pandemic preparedness
- GloPID- R members have endorsed coordinated funding as a priority
- Agreement with GACD secretariat to collaborate (mentoring and learning from their experience)
- Recruitment and Embedment of Programme Manager in GACD office in London for the first call(s)
- Engaging interested GloPID-R members in a roundtable
- Selecting and agreeing on call topic(s)
- Aim: Opening a first call in late 2023



GloPID-R Regional Hub development


Connecting clinical trial networks and funders to improve coordination

Aim: To strengthen GloPID-R’s capacity as a meta-organisation to improve efficiency of research funding for pandemic preparedness and response.

Objectives:

- Focus on capacity strengthening and improved engagement with local funders
- Strengthening of regional research networks and preparedness platforms, involving local funding agencies
- Facilitate regional research priority setting in advance of future pandemics
- Facilitate sustainable demand-led capacity strengthening aligned with regional needs and gaps
- Strengthen regional capacity for research to policy uptake
- Facilitate the coordination of funding for **global** preparedness and response

- African Hub to be hosted by South African MRC - in kind commitment for 3 years
- Funding provided by UKDHSC via EDCTP
- Mapping of stakeholder exercise - Dec 2022
- Kick off meeting - Spring 2023



- South Korea volunteered to host Asia-Pacific Hub
- Advisory Committee Chaired by Japan, members: Australia, Singapore
- Mapping of stakeholders conducted
- First kick off meeting on Nov 10-11th, 2022

GloPID-R 3.0



www.glopid-r.org



The GloPID-R Secretariat is a project which receives funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 874667.